Getting to value in neurological care: A roadmap for academic neurology

Annals of Neurology

Volumn 69, Issue 6, 2011, Pages 909-918

  Holloway, Robert G ^a,c   Ringel, Steven P ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Box 673 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; DABIGATRAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STEROID; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTICOAGULATION; ARTICLE; BELL PALSY; BRAIN TUMOR; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEMENTIA; DRUG COST; EDUCATION; ENVIRONMENTAL FACTOR; EPILEPSY; HEADACHE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; NEUROLOGY; NEUROPATHY; OBSERVATIONAL STUDY; PARKINSON DISEASE; PATIENT CARE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; STROKE; STUDY DESIGN;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; NEUROLOGY; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT PROTECTION AND AFFORDABLE CARE ACT;

EID: 79959406793     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22439     Document Type: Article

References (67)

1. Fan E, Laupacis A, Pronovost PJ, et al. How to use an article about quality improvement. JAMA 2010; 304: 2279-2287.
2. Reeves MJ, Parker C, Fonarow GC, et al. Development of stroke performance measures: definitions, methods, and current measures. Stroke 2010; 41: 1573-1578.
3. Cheng EM, Tonn S, Swain-Eng R, et al. Quality improvement in neurology: AAN Parkinson disease quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology. Neurology 2010; 75: 2021-2027.
4. Fountain NB, Van Ness PC, Swain-Eng R, et al. Quality improvement in neurology: AAN epilepsy quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology. Neurology 2011; 76: 94-99.
5. Cheng EM, Crandall CJ, Bever CT Jr, et al. Quality indicators for multiple sclerosis. Mult Scler 2010; 16: 970-980.
6. Perry M, Draskovic I, van Achterberg T, et al. Development and validation of quality indicators for dementia diagnosis and management in a primary care setting. J Am Geriatr Soc 2010; 58: 557-563.
7. Chassin MR, Loeb JM, Schmaltz SP, Wachter RM,. Accountability measures-using measurement to promote quality improvement. N Engl J Med 2010; 363: 683-688.
8. Porter ME,. What is value in health care? N Engl J Med 2010; 363: 2477-2481.
9. Mountford J, Davie C,. Toward an outcomes-based health care system: a view from the United Kingdom. JAMA 2010; 304: 2407-2408.
10. Shahian DM, Wolf RE, Iezzoni LI, et al. Variability in the measurement of hospital-wide mortality rates. N Engl J Med 2010; 363: 2530-2539.
11. Wu AW, Snyder C, Clancy CM, Steinwachs DM,. Adding the patient perspective to comparative effectiveness research. Health Aff (Millwood) 2010; 29: 1863-1871.
12. Bever CT Jr, Franklin GM, Kaufman JM, Esper GJ,. Role of professionalism in improving the patient-centeredness, timeliness, and equity of neurological care. Arch Neurol 2010; 67: 1386-1390.
13. Epstein RM, Fiscella K, Lesser CS, Stange KC,. Why the nation needs a policy push on patient-centered health care. Health Aff (Millwood) 2010; 29: 1489-1495.
14. Sepucha KR, Levin CA, Uzogara EE, et al. Developing instruments to measure the quality of decisions: early results for a set of symptom-driven decisions. Patient Educ Couns 2008; 73: 504-510.
15. Levinson W, Lesser CS, Epstein RM,. Developing physician communication skills for patient-centered care. Health Aff (Millwood) 2010; 29: 1310-1318.
16. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. December, 2009. Available at:. Accessed April 12, 2011.
17. Gershon RC, Cella D, Fox NA, et al. Assessment of neurological and behavioural function: the NIH toolbox. Lancet Neurol 2010; 9: 138-139.
18. National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH). Neuro-QOL-quality of life in neurological disorders. 2010. Available at:. Accessed April 12, 2011.
19. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010; 67: 64-70.
20. Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS). Talking Quality. Health Care Report Card Compendium. 2010. Available at:. Accessed April 12, 2011.
21. Kelly A, Thompson JP, Tuttle D, et al. Public reporting of quality data for stroke: is it measuring quality? Stroke 2008; 39: 3367-3371.
22. Physician payment sunshine provisions: Patient protection affordable care act passed the house. Available at:. Accessed April 12, 2011.
23. Benner JS, Morrison MR, Karnes EK, et al. An evaluation of recent federal spending on comparative effectiveness research: priorities, gaps, and next steps. Health Aff (Millwood) 2010; 29: 1768-1776.
24. Committee on Comparative Effectiveness Research Prioritization, Board on Health Care Services, Institute of Medicine. Initial national priorities for comparative effectiveness research. Washington, DC: The National Academies Press, 2009. Available at:. Accessed April 12, 2011.
25. U.S. Department of Health and Human Services. Federal Coordinating Council for Comparative Effectiveness Research. Report to the president and congress. Washington, DC: U.S. Department of Health & Human Services, 2009. Available at:. Accessed April 12, 2011.
26. Selker HP, Strom BL, Ford DE, et al. White paper on CTSA consortium role in facilitating comparative effectiveness research: September 23, 2009 CTSA consortium strategic goal committee on comparative effectiveness research. Clin Transl Sci 2010; 3: 29-37.
27. Garrison LP Jr, Neumann PJ, Radensky P, Walcoff SD,. A flexible approach to evidentiary standards for comparative effectiveness research. Health Aff (Millwood) 2010; 29: 1812-1817.
28. Johnston SC, Hauser SL,. Comparative effectiveness research in the neurosciences. Ann Neurol 2009; 65: A6-A8.
29. Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362: 790-799.
30. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64: 1868-1873. (Pubitemid 40800699)
31. Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363: 11-23.
32. Hochman M, McCormick D,. Characteristics of published comparative effectiveness studies of medications. JAMA 2010; 303: 951-958.
33. Chokshi DA, Avorn J, Kesselheim AS,. Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. Health Aff (Millwood) 2010; 29: 1842-1848.
34. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-1053. (Pubitemid 38915945)
35. Dreyer NA, Tunis SR, Berger M, et al. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood) 2010; 29: 1818-1825.
36. Fleurence RL, Naci H, Jansen JP,. The critical role of observational evidence in comparative effectiveness research. Health Aff (Millwood) 2010; 29: 1826-1833.
37. Bradley WG, Anderson F, Bromberg M, et al. Current management of ALS: comparison of the ALS CARE database and the AAN practice parameter. the American Academy of Neurology. Neurology 2001; 57: 500-504. (Pubitemid 32757600)
38. Miller RG, Anderson F, Brooks BR, et al. Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database. Ann Neurol 2009; 65 (Suppl 1): S24-S28.
39. Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303: 1401-1409.
40. Saporta AS, Sottile S, Miller L, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011; 69: 22-33.
41. Thompson JP, Noyes K, Dorsey ER, et al. Quantitative risk-benefit analysis of natalizumab. Neurology 2008; 71: 357-364.
42. Bonham AC, Solomon MZ,. Moving comparative effectiveness research into practice: implementation science and the role of academic medicine. Health Aff (Millwood) 2010; 29: 1901-1905.
43. Bushnell CD, Zimmer LO, Pan W, et al. Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol 2010; 67: 1456-1463.
44. Avorn J, Fischer M,. 'Bench to behavior': translating comparative effectiveness research into improved clinical practice. Health Aff (Millwood) 2010; 29: 1891-1900.
45. Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke. Circ Cardiovasc Qual Outcomes 2010; 3: 291-302.
46. Vickrey BG, Mittman BS, Connor KI, et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. Ann Intern Med 2006; 145: 713-726. (Pubitemid 351650351)
47. Gifford DR, Holloway RG, Frankel MR, et al. Improving adherence to dementia guidelines through education and opinion leaders. A randomized, controlled trial. Ann Intern Med 1999; 131: 237-246. (Pubitemid 29383652)
48. Tufts Medical Center. Cost-effectiveness analysis registry. Available at:. Accessed April 12, 2011.
49. Ehlers L, Andersen G, Clausen LB, et al. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 2007; 38: 85-89. (Pubitemid 46035611)
50. Nguyen-Huynh MN, Johnston SC,. Is hospitalization after TIA cost-effective on the basis of treatment with tPA? Neurology 2005; 65: 1799-1801.
51. Hernandez RA, Sullivan F, Donnan P, et al. Economic evaluation of early administration of prednisolone and/or aciclovir for the treatment of Bell's palsy. Fam Pract 2009; 26: 137-144.
52. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. results of an international randomized trial. the EC/IC Bypass Study Group. N Engl J Med 1985; 313: 1191-1200.
53. Esselink RA, de Bie RM, de Haan RJ, et al. Long-term superiority of subthalamic nucleus stimulation over pallidotomy in Parkinson disease. Neurology 2009; 73: 151-153.
54. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
55. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.
56. Bor AS, Koffijberg H, Wermer MJ, Rinkel GJ,. Optimal screening strategy for familial intracranial aneurysms: a cost-effectiveness analysis. Neurology 2010; 74: 1671-1679.
57. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology (in press) 2011.
58. Nelson AL, Cohen JT, Greenberg D, Kent DM,. Much cheaper, almost as good: decrementally cost-effective medical innovation. Ann Intern Med 2009; 151: 662-667.
59. Manca A, Epstein DM, Torgerson DJ, et al. Randomized trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: cost-effectiveness analysis. Int J Technol Assess Health Care 2006; 22: 67-75. (Pubitemid 43376241)
60. Jarvik JG, Hollingworth W, Martin B, et al. Rapid magnetic resonance imaging vs radiographs for patients with low back pain: a randomized controlled trial. JAMA 2003; 289: 2810-2818. (Pubitemid 37430116)
61. Neumann PJ, Weinstein MC,. Legislating against use of cost-effectiveness information. N Engl J Med 2010; 363: 1495-1497.
62. Garber AM, Sox HC,. The role of costs in comparative effectiveness research. Health Aff (Millwood) 2010; 29: 1805-1811.
63. Brook RH,. The end of the quality improvement movement: long live improving value. JAMA 2010; 304: 1831-1832.
64. Lee TH,. Putting the value framework to work. N Engl J Med 2010; 363: 2481-2483.
65. Keroack MA, Youngberg BJ, Cerese JL, et al. Organizational factors associated with high performance in quality and safety in academic medical centers. Acad Med 2007; 82: 1178-1186. (Pubitemid 350211580)
66. Behal R, Finn J,. Understanding and improving inpatient mortality in academic medical centers. Acad Med 2009; 84: 1657-1662.
67. Etheredge LM,. Creating a high-performance system for comparative effectiveness research. Health Aff (Millwood) 2010; 29: 1761-1767.